Plasma mevalonate as a measure of cholesterol synthesis in man
about
Antiviral activity of lovastatin against respiratory syncytial virus in vivo and in vitroLack of effect of lovastatin therapy on the parameters of whole-body cholesterol metabolismPharmacodynamic effects and pharmacokinetics of atorvastatin after administration to normocholesterolemic subjects in the morning and evening.Role of the kidneys in the metabolism of plasma mevalonate. Studies in humans and in rhesus monkeysIn vivo regulation of human mononuclear leukocyte 3-hydroxy-3-methylglutaryl coenzyme A reductase. Studies in normal subjects.Suppression of apolipoprotein B production during treatment of cholesteryl ester storage disease with lovastatin. Implications for regulation of apolipoprotein B synthesisThe toxicology of HMG-CoA reductase inhibitors: prediction of human risk.No evidence for mevalonate shunting in moderately affected children with Smith-Lemli-Opitz syndromeThe influence of sleep and sleep loss upon food intake and metabolism.Determination of key intermediates in cholesterol and bile acid biosynthesis by stable isotope dilution mass spectrometry.Impact of SLCO1B1 (OATP1B1) and ABCG2 (BCRP) genetic polymorphisms and inhibition on LDL-C lowering and myopathy of statins.Probucol: pharmacology and clinical application.Inhibition of hydroxymethylglutaryl coenzyme A reductase activity does not affect the secretion rate of apolipoproteins B and AI by CaCo-2 cells.Human breath isoprene and its relation to blood cholesterol levels: new measurements and modeling.Carbamazepine increases atherogenic lipoproteins: mechanism of action in male adults.Feedback inhibition of the cholesterol biosynthetic pathway in patients with Smith-Lemli-Opitz syndrome as demonstrated by urinary mevalonate excretion.Endogenous cholesterol synthesis is associated with VLDL-2 apoB-100 production in healthy humans.The influence of dosing time, variable compliance and circadian low-density lipoprotein production on the effect of simvastatin: simulations from a pharmacokinetic-pharmacodynamic model.Effects of multiple ascending doses of the glucagon receptor antagonist PF-06291874 in patients with type 2 diabetes mellitus.Role of GH in regulating nocturnal rates of lipolysis and plasma mevalonate levels in normal and diabetic humans.Quantification of urinary mevalonic acid as a biomarker of HMG-CoA reductase activity by a novel translational LC–MS/MS methodIncreased nonsterol isoprenoids, dolichol and ubiquinone, in the Smith-Lemli-Opitz syndrome: effects of dietary cholesterolThe Evening versus Morning Polypill Utilization Study: the TEMPUS rationale and design
P2860
Q28360752-2778F35B-A0B1-4ED5-BC05-0E4E2F3B1C48Q34260272-EF67C803-3477-4536-9599-95D1AC0C3883Q34400852-98C50D57-EE14-404A-AF00-70AE61B14FF0Q34540185-72AD5D56-7997-40DB-A7AF-72F8F26E3AF9Q34567141-AF104DB3-8728-4C54-B124-DCDA2645B20CQ35583380-5A69E7A6-E514-4FB0-9875-B3C5F474E41FQ35927194-D3ED3C24-D4E7-4B81-86F9-3CBDAC03ECB2Q36113692-85F3784E-BB2E-461B-B019-DC30044CCF0BQ37349999-11BCCF84-4268-42FA-8078-ADAA12C5F573Q37553945-97683D95-D436-477F-ABB0-E9545D14A0AEQ37855801-80185D47-6694-4A07-9618-E61B267B4BBFQ38142170-53C37654-2E2A-483F-A47E-8A11D7BFBBF9Q42482221-F28324E6-80F4-4669-A7B4-81CB38A6E993Q43678622-69DB2A59-B984-41E7-8F67-642DE3908A02Q43852715-73D72134-4CEE-408E-9A93-27DA024575CCQ44168299-B5F414A3-17BD-4AD0-9F86-4AE3F88643A9Q44406779-E61C51BE-916C-41E6-A706-AF988B77C05BQ44490880-4F5C4E8F-730B-42D6-9738-D61A69FE9E58Q51286181-A4FC05F4-684E-4BEB-AA3D-176C3BC9AD69Q51604958-151B2D5B-0929-4BDF-9063-9848A95DAC6EQ57302651-78FE4D3A-021F-46C1-8CEA-96CDEEAFA738Q57375104-750AC2CB-91EF-4D90-AC9A-234D07A276C4Q57583148-D9AB8721-A99D-472A-8988-8A417D1DF896
P2860
Plasma mevalonate as a measure of cholesterol synthesis in man
description
1984 nî lūn-bûn
@nan
1984 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
1984 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
1984年の論文
@ja
1984年論文
@yue
1984年論文
@zh-hant
1984年論文
@zh-hk
1984年論文
@zh-mo
1984年論文
@zh-tw
1984年论文
@wuu
name
Plasma mevalonate as a measure of cholesterol synthesis in man
@ast
Plasma mevalonate as a measure of cholesterol synthesis in man
@en
Plasma mevalonate as a measure of cholesterol synthesis in man
@nl
type
label
Plasma mevalonate as a measure of cholesterol synthesis in man
@ast
Plasma mevalonate as a measure of cholesterol synthesis in man
@en
Plasma mevalonate as a measure of cholesterol synthesis in man
@nl
prefLabel
Plasma mevalonate as a measure of cholesterol synthesis in man
@ast
Plasma mevalonate as a measure of cholesterol synthesis in man
@en
Plasma mevalonate as a measure of cholesterol synthesis in man
@nl
P2093
P2860
P356
P1476
Plasma mevalonate as a measure of cholesterol synthesis in man
@en
P2093
A W Alberts
D J McNamara
E H Ahrens
P J De Schepper
T S Parker
P2860
P304
P356
10.1172/JCI111495
P407
P577
1984-09-01T00:00:00Z